Grape King Bio Ltd (1707.TW)
TWD 151.0
(0.0%)
TWD 151.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.88 Billion TWD | -6.12% |
| 2022 | 3.14 Billion TWD | 10.33% |
| 2021 | 2.84 Billion TWD | 1.4% |
| 2020 | 2.79 Billion TWD | 1.1% |
| 2019 | 2.76 Billion TWD | 2.66% |
| 2018 | 2.69 Billion TWD | 2.16% |
| 2017 | 2.64 Billion TWD | 3.69% |
| 2016 | 2.55 Billion TWD | 24.19% |
| 2015 | 2.05 Billion TWD | 13.07% |
| 2014 | 1.81 Billion TWD | 17.31% |
| 2013 | 1.55 Billion TWD | 35.82% |
| 2012 | 1.13 Billion TWD | 22.58% |
| 2011 | 917.13 Million TWD | 19.14% |
| 2010 | 785.39 Million TWD | 20.21% |
| 2009 | 677.36 Million TWD | 29.42% |
| 2008 | 404.99 Million TWD | 18.97% |
| 2007 | 434.21 Million TWD | 25.88% |
| 2006 | 346.92 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 674.22 Million TWD | 19.17% |
| 2024 Q1 | 557.72 Million TWD | -36.41% |
| 2023 Q2 | 720.37 Million TWD | 15.42% |
| 2023 Q1 | 624.12 Million TWD | -36.35% |
| 2023 Q4 | 938.34 Million TWD | 17.66% |
| 2023 Q3 | 797.48 Million TWD | 10.7% |
| 2023 FY | - TWD | -6.12% |
| 2022 Q3 | 786.5 Million TWD | -3.39% |
| 2022 FY | - TWD | 10.33% |
| 2022 Q2 | 814.1 Million TWD | 45.71% |
| 2022 Q1 | 558.73 Million TWD | -38.65% |
| 2022 Q4 | 980.53 Million TWD | 24.67% |
| 2021 Q3 | 713.3 Million TWD | 5.69% |
| 2021 FY | - TWD | 1.4% |
| 2021 Q1 | 547.35 Million TWD | -38.61% |
| 2021 Q2 | 674.93 Million TWD | 23.31% |
| 2021 Q4 | 910.77 Million TWD | 27.68% |
| 2020 Q1 | 600.83 Million TWD | -30.6% |
| 2020 Q3 | 688.2 Million TWD | 9.78% |
| 2020 Q4 | 891.62 Million TWD | 29.56% |
| 2020 Q2 | 626.87 Million TWD | 4.33% |
| 2020 FY | - TWD | 1.1% |
| 2019 FY | - TWD | 2.66% |
| 2019 Q3 | 672.07 Million TWD | 0.9% |
| 2019 Q2 | 666.07 Million TWD | 16.23% |
| 2019 Q1 | 573.07 Million TWD | -31.4% |
| 2019 Q4 | 865.74 Million TWD | 28.82% |
| 2018 Q1 | 537.62 Million TWD | -35.43% |
| 2018 Q4 | 835.44 Million TWD | 21.17% |
| 2018 Q3 | 689.49 Million TWD | 7.79% |
| 2018 FY | - TWD | 2.16% |
| 2018 Q2 | 639.68 Million TWD | 18.98% |
| 2017 Q3 | 631.27 Million TWD | -4.83% |
| 2017 Q1 | 520.58 Million TWD | -27.98% |
| 2017 Q2 | 663.29 Million TWD | 27.41% |
| 2017 Q4 | 832.57 Million TWD | 31.89% |
| 2017 FY | - TWD | 3.69% |
| 2016 Q1 | 558.3 Million TWD | -5.85% |
| 2016 FY | - TWD | 24.19% |
| 2016 Q4 | 722.84 Million TWD | 12.68% |
| 2016 Q3 | 641.51 Million TWD | 1.69% |
| 2016 Q2 | 630.83 Million TWD | 12.99% |
| 2015 Q2 | 488.62 Million TWD | 7.66% |
| 2015 Q1 | 453.87 Million TWD | -17.53% |
| 2015 FY | - TWD | 13.07% |
| 2015 Q4 | 592.98 Million TWD | 13.9% |
| 2015 Q3 | 520.63 Million TWD | 6.55% |
| 2014 Q3 | 463.49 Million TWD | 10.29% |
| 2014 Q2 | 420.23 Million TWD | 9.34% |
| 2014 Q1 | 384.33 Million TWD | -19.89% |
| 2014 FY | - TWD | 17.31% |
| 2014 Q4 | 550.36 Million TWD | 18.74% |
| 2013 Q4 | 479.77 Million TWD | 20.3% |
| 2013 Q2 | 362.31 Million TWD | 17.16% |
| 2013 FY | - TWD | 35.82% |
| 2013 Q1 | 309.23 Million TWD | 0.37% |
| 2013 Q3 | 398.82 Million TWD | 10.08% |
| 2012 Q3 | 303.72 Million TWD | 14.78% |
| 2012 Q2 | 264.61 Million TWD | 2.64% |
| 2012 Q1 | 257.82 Million TWD | -6.93% |
| 2012 FY | - TWD | 22.58% |
| 2012 Q4 | 308.09 Million TWD | 1.44% |
| 2011 Q2 | 264.38 Million TWD | 13.43% |
| 2011 Q1 | 233.07 Million TWD | -10.24% |
| 2011 Q4 | 277 Million TWD | 76.83% |
| 2011 FY | - TWD | 19.14% |
| 2011 Q3 | 156.65 Million TWD | -40.75% |
| 2010 Q4 | 259.65 Million TWD | 54.27% |
| 2010 FY | - TWD | 20.21% |
| 2010 Q3 | 168.31 Million TWD | -21.33% |
| 2010 Q2 | 213.96 Million TWD | 53.29% |
| 2010 Q1 | 139.58 Million TWD | 0.0% |
| 2009 FY | - TWD | 29.42% |
| 2008 FY | - TWD | 18.97% |
| 2007 FY | - TWD | 25.88% |
| 2006 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Standard Chem & Pharm CO., LTD. | 1.57 Billion TWD | -82.711% |
| Maywufa Company Ltd. | 239.81 Million TWD | -1103.003% |
| ScinoPharm Taiwan, Ltd. | 819.15 Million TWD | -252.189% |
| Lotus Pharmaceutical Co., Ltd. | 6.87 Billion TWD | 58.012% |
| LIWANLI Innovation Co., Ltd. | 6.81 Million TWD | -42263.715% |
| YungShin Global Holding Corporation | 1.35 Billion TWD | -112.542% |
| PhytoHealth Corporation | -20.69 Million TWD | 14038.395% |
| SCI Pharmtech, Inc. | 529.61 Million TWD | -444.732% |
| Formosa Laboratories, Inc. | 1.16 Billion TWD | -147.998% |
| PharmaEssentia Corporation | -671.48 Million TWD | 529.639% |
| Bora Pharmaceuticals Co., LTD. | 5.73 Billion TWD | 49.689% |